KV Pharmaceutical has entered an employment agreement with interim president and CEO David Van Vliet, with a term through Dec. 31, 2011. Van Vliet has served as interim president and CEO since December 2008.
Infinity Pharmaceuticals has announced that Adelene Perkins will become the company's president and CEO. She also will join the company's board of directors. Steven Holtzman, Infinity's founder, and current chair and CEO, will continue full-time involvement with the company as executive chair of the board.
Dutch biotech company Pepscan Holding has appointed Wim Mol as its new CEO.
NormOxys has appointed Martin Tolar as company's president and CEO. The company also announced it has leased a 3,500 square-foot space in Wellesley, MA, to serve as its new corporate headquarters.
EUCODIS Bioscience has appointed current CFO Thomas Fischer as its new CEO.
Jazz Pharmaceuticals has tapped Kathryn Falberg as its CFO. Falberg previously worked at ARCA biopharma, where she served as CFO and Chief Operating Officer.
CSL Limited has made a number of changes in its organization structure and its senior executive group. Peter Turner will become COO and join Board as an executive director. Tony Cipa has advised the Company that he will retire from his position as executive director and CFO in October 2010. At that time, he will be replaced as CFO by Gordon Naylor and will stand down from the CSL Board.
SOHM has appointed Shaunak Parikh as VP of operations.
Idera Pharmaceuticals announced the appointment of Rahul Jasuja, Ph.D., as VP of corporate development.
Opexa Therapeutics has hired Jaye Thompson to lead the company's efforts to further the clinical development of Tovaxin, its flagship MS therapy. Dawn McGuire, Opexa's expert clinical advisor and member of the clinical advisory board, has agreed to represent company as its acting chief medical officer.
Newly formed Envoy Therapeutics has announced that former Senator Bill Bradley has joined its Board of Directors. Report
Robert Zerbe, president and CEO of QuatRx, has joined Optimer Pharmaceuticals' board of directors.
NovaDigm Therapeutics has tapped R. Gordon Douglas, Jr. to be chairman of the company's board of directors.
Francesco Bellini has resigned as Gentium's chairman and a member of its board of directors. Bellini was elected to Gentium's board in October.
Xencor has announced that Bruce Carter, will become chairman of the board. Carter was most recently chief executive officer of ZymoGenetics.
Æterna Zentaris has announced the appointment of Pierre Lapalme to its board of directors.
Sirona Biochem has made the fourth major appointment this month to its Scientific Advisory Board--Professor B. Mario Pinto--one of Canada's leading chemical biologists.